Kodiak Sciences (NASDAQ:KOD) Price Target Raised to $80.00

Kodiak Sciences (NASDAQ:KOD) had its price objective hoisted by UBS Group from $50.00 to $80.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. UBS Group’s price target indicates a potential upside of 89.07% from the company’s current price.

A number of other research firms have also recently issued reports on KOD. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and set a $58.00 price target (up from $38.00) on shares of Kodiak Sciences in a report on Friday. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Kodiak Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $35.43.

Kodiak Sciences Trading Up 6.4%

Shares of Kodiak Sciences stock traded up $2.55 during trading on Friday, hitting $42.31. 2,867,426 shares of the stock were exchanged, compared to its average volume of 934,248. Kodiak Sciences has a 1-year low of $1.92 and a 1-year high of $45.60. The stock has a market capitalization of $2.24 billion, a price-to-earnings ratio of -10.25 and a beta of 2.61. The company has a fifty day moving average price of $24.95 and a 200-day moving average price of $21.62.

Hedge Funds Weigh In On Kodiak Sciences

Large investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC boosted its stake in Kodiak Sciences by 1,221.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after purchasing an additional 916 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Kodiak Sciences during the fourth quarter worth $29,000. Headlands Technologies LLC lifted its holdings in shares of Kodiak Sciences by 256.4% during the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock worth $30,000 after buying an additional 5,815 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Kodiak Sciences in the fourth quarter valued at about $72,000. Finally, Strs Ohio bought a new stake in shares of Kodiak Sciences in the fourth quarter valued at about $87,000. Institutional investors own 89.06% of the company’s stock.

Trending Headlines about Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Topline Phase 3 GLOW2 results showed Zenkuda’s superiority vs. sham on the trial’s primary endpoint (large DRSS improvements), supporting the program’s previously reported GLOW1 success and paving the way toward a regulatory filing. PR Newswire: GLOW2 Topline Results
• Positive Sentiment: Mainstream press and market outlets are reporting the trial win and the stock rally, driving increased investor attention and heavy trading. Widespread coverage increases the likelihood of more short‑term inflows. Reuters: Shares Surge After Late‑Stage Success
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and raised its price target to $58 (from $38), implying significant upside vs. recent levels — a bullish analyst signal that can attract additional institutional interest. Benzinga: HC Wainwright Price‑Target Raise
• Neutral Sentiment: Industry press notes Kodiak expects to move toward a BLA/filing next after the twin Phase 3 successes — a clear path to commercialization but still subject to regulatory review and timelines. This is constructive long term but timing and approval risk remain. BioWorld: BLA Filing Next
• Negative Sentiment: Options activity showed an unusual surge in put buying (3,472 puts, a ~1,256% jump vs. typical daily put volume), suggesting some traders are hedging or betting on pullbacks amid the sharp rally.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.